Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of The American Academy of Dermatology Année : 2023

Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort

1 CHU Nice - Centre Hospitalier Universitaire de Nice
2 Centre Léon Bérard [Lyon]
3 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
4 OncoThAI - Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189
5 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
6 PCCEI - Pathogenesis and Control of Chronic and Emerging Infections
7 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
8 Service de Dermatologie (CHU de Dijon)
9 CHU Bordeaux
10 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
11 CHRU Brest - Centre Hospitalier Régional Universitaire de Brest
12 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
13 Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
14 Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM]
15 Hôpital Ambroise Paré [AP-HP]
16 UVSQ - Université de Versailles Saint-Quentin-en-Yvelines
17 BECCOH - Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie
18 Hôpital Avicenne [AP-HP]
19 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes
20 IRCM - U1194 Inserm - UM - Institut de Recherche en Cancérologie de Montpellier
21 Service de Dermatologie et Allergologie [CHRU Nancy]
22 CHU Amiens-Picardie
23 Service de Dermatologie [AP-HP Hôpital Saint-Louis]
24 HIPI (UMR_S_976 / U976) - Immunologie humaine, physiopathologie & immunothérapie
25 AP-HP - Hopital Saint-Louis [AP-HP]
26 Hôpital Hôtel-Dieu [Paris]
27 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
28 Service de Dermatologie [Nice]
29 C3M - Centre méditerranéen de médecine moléculaire
Sophie Dalac
Caroline Dutriaux
  • Fonction : Auteur
Eve Maubec

Résumé

Background: Clinical outcomes of advanced melanoma of unknown primary (MUP) in the era of novel therapies have been scarcely studied. Objective: To investigate the efficacy and safety of systemic treatments in patients with advanced MUP compared to patients with stage-matched melanoma of known cutaneous primary (cMKP). Methods: Based on the nationwide MelBase prospective database, this study included advanced melanoma patients treated from March 2013 to June 2021 with first-line immunotherapies, targeted therapies, or chemotherapy. Co-primary outcomes were progression-free survival and overall survival. Secondary outcome was treatment-related toxicities. Multivariate and propensity score analyses were performed. Results: Of 1882 patients, 265 (14.1%) had advanced MUP. Patients with advanced MUP displayed more often unfavorable initial prognostic factors than those with cMKP. Progression-free and overall survival did not differ significantly between the groups (P = .73 and P = .93, respectively), as well as treatment-related toxicity rate and severity, regardless of treatment type. Limitations: No record of standard diagnostic criteria of MUP used in the participating centers. Conclusions: Although patients with MUP had less favorable baseline prognostic factors, they benefited from the novel therapies as much as those with cMKP. They should be managed according to similar strategies.
Fichier non déposé

Dates et versions

hal-04052676 , version 1 (30-03-2023)

Identifiants

Citer

Perrine Rousset, Stéphane Dalle, Laurent Mortier, Olivier Dereure, Sophie Dalac, et al.. Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort. Journal of The American Academy of Dermatology, 2023, 88 (4), pp.808-815. ⟨10.1016/j.jaad.2022.11.040⟩. ⟨hal-04052676⟩
42 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More